PCRX Valuation

Pacira Biosciences Inc

Add to Watchlist

Advanced Chart

25.840

+0.45(1.772%)1D

Overview
Forecast
Valuation
Earnings

PCRX Relative Valuation

PCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PCRX is overvalued; if below, it's undervalued.

Historical Valuation

Pacira Biosciences Inc (PCRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 8.33 is considered Undervalued compared with the five-year average of 13.74. The fair price of Pacira Biosciences Inc (PCRX) is between 46.70 to 74.72 according to relative valuation methord. Compared to the current price of 25.64 USD , Pacira Biosciences Inc is Undervalued By 45.1%.

Relative Value

Fair Zone

46.70-74.72

Current Price：25.64

45.1%

Undervalued

8.46

Trailing

Forward

6.15

EV/EBITDA

Pacira Biosciences Inc. (PCRX) has a current EV/EBITDA of 6.15. The 5-year average EV/EBITDA is 9.59. The thresholds are as follows: Strongly Undervalued below 3.09, Undervalued between 3.09 and 6.34, Fairly Valued between 12.85 and 6.34, Overvalued between 12.85 and 16.10, and Strongly Overvalued above 16.10. The current Forward EV/EBITDA of 6.15 falls within the Undervalued range.

6.85

EV/EBIT

Pacira Biosciences Inc. (PCRX) has a current EV/EBIT of 6.85. The 5-year average EV/EBIT is 10.73. The thresholds are as follows: Strongly Undervalued below 3.67, Undervalued between 3.67 and 7.20, Fairly Valued between 14.27 and 7.20, Overvalued between 14.27 and 17.80, and Strongly Overvalued above 17.80. The current Forward EV/EBIT of 6.85 falls within the Undervalued range.

1.44

Pacira Biosciences Inc. (PCRX) has a current PS of 1.44. The 5-year average PS is 3.04. The thresholds are as follows: Strongly Undervalued below 0.22, Undervalued between 0.22 and 1.63, Fairly Valued between 4.44 and 1.63, Overvalued between 4.44 and 5.85, and Strongly Overvalued above 5.85. The current Forward PS of 1.44 falls within the Undervalued range.

5.74

P/OCF

Pacira Biosciences Inc. (PCRX) has a current P/OCF of 5.74. The 5-year average P/OCF is 10.73. The thresholds are as follows: Strongly Undervalued below 0.53, Undervalued between 0.53 and 5.63, Fairly Valued between 15.83 and 5.63, Overvalued between 15.83 and 20.92, and Strongly Overvalued above 20.92. The current Forward P/OCF of 5.74 falls within the Historic Trend Line -Fairly Valued range.

6.49

P/FCF

Pacira Biosciences Inc. (PCRX) has a current P/FCF of 6.49. The 5-year average P/FCF is 14.64. The thresholds are as follows: Strongly Undervalued below -6.22, Undervalued between -6.22 and 4.21, Fairly Valued between 25.07 and 4.21, Overvalued between 25.07 and 35.49, and Strongly Overvalued above 35.49. The current Forward P/FCF of 6.49 falls within the Historic Trend Line -Fairly Valued range.

Pacira Biosciences Inc (PCRX) has a current Price-to-Book (P/B) ratio of 1.48. Compared to its 3-year average P/B ratio of 1.80 , the current P/B ratio is approximately -17.76% higher. Relative to its 5-year average P/B ratio of 2.77, the current P/B ratio is about -46.63% higher. Pacira Biosciences Inc (PCRX) has a Forward Free Cash Flow (FCF) yield of approximately 10.34%. Compared to its 3-year average FCF yield of 12.02%, the current FCF yield is approximately -13.94% lower. Relative to its 5-year average FCF yield of 8.17% , the current FCF yield is about 26.55% lower.

1.50

P/B

Median3y

1.80

Median5y

2.77

10.43

FCF Yield

Median3y

12.02

Median5y

8.17

Competitors Valuation Multiple

The average P/S ratio for PCRX's competitors is 13.96, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX) exhibits a P/S ratio of 1.44, which is -89.69% above the industry average. Given its robust revenue growth of 1.73%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PCRX.O

Pacira Biosciences Inc

LENZ Therapeutics Inc

55.41

1.14B

Performance Decomposition

Market capitalization of PCRX increased by 66.07% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.12 to -9.05.

The secondary factor is the Revenue Growth, contributed 1.73%to the performance.

Overall, the performance of PCRX in the past 1 year is driven by P/E Change. Which is more unsustainable.

1.73%

178.02M → 181.10M

Revenue Growth

-125.26%

10.61 → -2.68

Margin Expansion

189.60%

-3.12 → -9.05

P/E Change

66.07%